On August 28, 2020 Antengene, reported that three-year old Shanghai startup originally backed by Celgene, will conduct a Hong Kong IPO that is expected to raise $200 million (Press release, Antengene, AUG 28, 2020, View Source [SID1234564141]). Focused on oncology, Antengene has 12 projects in its portfolio, a mix of in-licensed drugs and in-house R&D that it expects to test as monotherapies and in combinations. Six of its assets have started clinical trials. Last month, the company completed a $97 million Series C financing. In 2018, Antengene announced a $162 million deal to develop four Karyopharm assets in China.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!